Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb trial of parenteral nutrition plus second-line chemotherapy versus best supportive nutritional care in progressive pancreatic adenocarcinoma
2008-004696-22Phase 3Terminated
- Sponsor
- Heidelberg University Hospital
- Start
- Feb 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil, SmofKabiven Peripheral and eicosapentaenoic acid + docosahexaenoic acid in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoint: Event-free survival. Started Feb 2009; status: terminated.
02
Drugs
oxaliplatinfluorouracilSmofKabiven Peripheraleicosapentaenoic acid + docosahexaenoic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2008-004696-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004696-22.